3sbio Sustainability Profile
3SBio Inc., a leading biopharmaceutical company headquartered in China, has established itself as a key player in the biotechnology industry since its founding in 1993. With a strong operational presence across major regions in Asia, 3SBio focuses on the development, manufacturing, and marketing of innovative therapies, particularly in the fields of oncology, nephrology, and autoimmune diseases. The company is renowned for its core products, including recombinant human erythropoietin and other biologics, which are distinguished by their high quality and efficacy. Over the years, 3SBio has achieved significant milestones, including successful product launches and strategic partnerships, solidifying its market position as a trusted provider of biopharmaceutical solutions. With a commitment to advancing healthcare, 3SBio continues to drive innovation and improve patient outcomes in the biopharmaceutical landscape.
DitchCarbon Score
How does 3sbio's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
3sbio's score of 24 is lower than 66% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
3sbio's reported carbon emissions
In 2024, 3SBio reported total carbon emissions of approximately 69,136,120 kg CO2e, comprising 13,304,070 kg CO2e from Scope 1 and 55,832,050 kg CO2e from Scope 2 emissions. In 2023, the company recorded total emissions of about 60,649,530 kg CO2e, with Scope 1 emissions at 11,663,450 kg CO2e and Scope 2 emissions at 48,986,080 kg CO2e. This indicates a significant increase in emissions from 2023 to 2024. 3SBio has not disclosed any Scope 3 emissions data, nor have they set specific reduction targets through initiatives such as the Science Based Targets initiative (SBTi). The company’s emissions data is sourced directly from 3SBio Inc. and is not cascaded from any parent organization. The company has demonstrated a commitment to transparency in its emissions reporting, but currently lacks formal reduction initiatives or pledges. As the industry increasingly focuses on sustainability, 3SBio's future commitments and strategies will be crucial in addressing climate change and reducing their carbon footprint.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|
| Scope 1 | 5,960,680 | 0,000,000 | 0,000,000 | 0,000,000 | 00,000,000 | 00,000,000 |
| Scope 2 | 42,724,590 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 |
| Scope 3 | - | - | - | - | - | - |
How Carbon Intensive is 3sbio's Industry?
How Carbon Intensive is 3sbio's Location?
3sbio's Climate Goals (2030 & 2050)
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
3sbio has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
